Health and Me

Tanya Dutt

Over 1 In 3 COVID Cases In US Now Are Because Of New ‘Nimbus’ Variant: Experts Flag This Painful Symptom

As the U.S. gears up for the peak summer travel season, a new COVID-19 variant known as NB.1.8.1—or informally, "Nimbus" has rapidly taken center stage in the ongoing pandemic landscape. First identified through international traveler screening in March 2025, the highly contagious Omicron subvariant is now responsible for an estimated 37% of COVID-19 cases in the country, according to the CDC’s latest two-week analysis ending June 7.

NB.1.8.1 is a descendant of the Omicron recombinant lineage XDV.1.5.1 and possesses several spike protein mutations that have the potential to make it more transmissible and immune-evading with respect to immunity developed from prior infections or vaccinations. Nicknamed "Nimbus" by Canadian evolutionary biologist T. Ryan Gregory, the moniker has picked up steam on social media and public health discourse.

Although total test positivity is still relatively low in the U.S. at approximately 3%, the swift rise of Nimbus to become the second most prevalent variant—second only to LP.8.1 at 38%—has raised alarm among virologists and public health professionals. Although present infection and hospitalization levels are still within control, experts are warning of the possibility of a summer spike akin to cycles experienced in earlier years.

<h2>What Are The Painful Tell-Tale Symptoms of <span rel="noindex">New Covid Variant</span>?</h2>

One of the clearest indicators of the NB.1.8.1 strain is a symptom described by patients as a "razor blade feeling" in the throat. This sore throat—dull and stabbing particularly when swallowing—is reported more often among Nimbus sufferers than in previous strains. Specialists advise rest, hydration, and painkillers to treat this symptom.

Other frequently reported symptoms are fatigue, nasal congestion, cough, fever, muscle pain, and mild breathing difficulties, in line with previous Omicron subvariants.

On May 23, the World Health Organization designated NB.1.8.1 as a "variant under monitoring," noting its rapid worldwide spread and potentially high mutations. As of May 18, it was reported in more than 22 nations and now accounts for more than 10.7% of cases of COVID-19 worldwide.

In the United States, sequences deposited at GISAID corroborate its presence in at least 14 states, with public health officials anticipating wider geographic spread over the next few weeks. Trends from foreign health agencies and increasing hospitalizations in the U.K. imply a worldwide trend of enhanced transmissibility despite incomplete sequencing data.

<h2>How Dangerous Is Nimbus COVID Variant?</h2>

Although Nimbus is certainly more infectious, to date, there is no indication that it produces more severe illness than the previous ones. The WHO and the CDC both confirm that authorized COVID-19 vaccines continue to work against this variant, although breakthrough infections may happen.

The United Kingdom Health Security Agency (UKHSA) recently posted a near 10% increase in COVID hospitalizations and a 6.9% rise in cases in one week. UKHSA's deputy director, Dr. Gayatri Amirthalingam, stressed the point that while the variant is spreading, there is no immediate evidence of heightened severity of disease.

<h2>Will Nimbus Lead to a U.S. Summer Surge?</h2>

In the past, COVID-19 has increased twice a year in the United States—in the winter and then in the summer months, from June through August. That has been the case since 2020, and having a new, more contagious variant coupled with more travel and gatherings could set off another wave.

Experts warn that while population immunity in the U.S. is very high—with more than 90% of Americans having been infected or vaccinated—immunity does fade over time. Couple this with the immune-evasive nature of NB.1.8.1, and the recipe for a possible surge in cases is there.

Presently, WHO claims that current vaccines are protective against Nimbus. New COVID vaccines for the 2025–2026 season, designed to address LP.8.1, are set to be distributed this fall. In a contentious decision, Health and Human Services Secretary Robert F. Kennedy Jr. stated that the vaccines will only be available for high-risk populations: persons above 65 years and persons between the ages of 12–64 with at least one comorbidity.

The CDC has also at the same time revised its guidelines, no longer advising routine COVID vaccination of healthy pregnant women and children—a step that most obstetricians and pediatricians object to.

With COVID wastewater levels still low and hospitalization rates stable, there is no need for mass panic. However, staying informed and cautious is key. Individuals experiencing symptoms like razor-sharp throat pain, fever, or congestion should consider testing, isolate if positive, and seek medical attention if symptoms worsen—especially if they belong to high-risk groups.

Visitors are urged to watch for regional strain patterns, maintain proper hygiene, and wear masks in crowded or poorly ventilated spaces during peak travel seasons.

NB.1.8.1, or the "Nimbus" strain, is another chapter in the continuing COVID-19 tale. Although it seems no worse than past strains, its speed and its sore, razor-like throat mark it as a reminder that the virus is still evolving.

Public health officials emphasize that vaccines continue to provide robust protection and must be employed as a first line of defense, particularly among those who are most vulnerable. While summer progresses, the emergence of Nimbus necessitates close observation, public awareness, and redoubled focus on preventive health.

Health Conditions A-Z

health

new covid variant

nb.1.8.1 symptoms

covid sore throat pain

new covid variant us 2025

omicron subvariant 2025

covid summer surge

razor blade throat covid

Lethal Fungus Is Spreading Across Many US States, Why Is It Concerning?

90% Of Young Men In Their 20s And 30s Are Unaware Of This Fast-Rising Cancer Threat

RFK Jr. Claims Seed Oils Are 'Poison' But This What They Actually Do To Your Body

Health News

Common Mistakes You May Be Making In The Gym

Strengthen Your Legs Muscles With These Exercises

Beat Anxiety With Books: How Reading Helps With Stress

Ghee For Health: Ayurvedic Health Benefits Of Clarified Butter

Common Mistakes You Are Making While Walking

Exercises You Should Do At Home When You Skip Gym

Common Mistakes You May Be Making While Working Out

Ways You Are Runing Your Weight Loss Journey

Beyond Fruits – How To Retain Hydration And Stay Safe In Summers

Can This Extremely Hot Weather Trigger Our Mental Health?

You Are Hurting Your Gut Health With These Habits

Avoid The Heat With These Indoor Exercises

Stay Sharp! Activities That Keep Cognitive Diseases At Bay

Protect Your Cardiovascular Health With These Heart Healthy Foods

Ways To Ease Nighttime Anxiety

Smoothie Ideas That Can Help With Weight Loss

Low Fat Foods That Are Actually Unhealthy

All Suryanamaskar Poses And How To Do Them

Do Changing Seasons Affect Your Weight?

Can Heatwave Affect Your Diet?

Heatwave To Monsoon: Health Concerns With Seasonal Changes

Standing Exercises That Help You Burn Calories

Reasons To Do Dancing As A Workout

Why Summer Fruits Are A Great Addition To Your Diet?

What Should You Avoid For Your Bladder?

Lower-Body Exercises For Strong Foundation

Healthy Drinks That Improve Your Digestion

World Tobacco Day: Unexpected Ways Smoking Can Affect You

Seasonal Mood Swings? How Weather Affects Mental Health

Is Calorie Counting Healthy? Dos And Don’ts

Heat-Related Illnesses That You Should Know

Menstrual Hygiene Day: Tips On Period Hygiene

​Add These High Protein Vegetarian Meals To Your Diet​

Top 10 Workouts That Burn Most Calorie

Makhana Season – Healthy &amp; Quick Foxnut Recipes

Monsoon Ahead – Tips On Building Rainy Season Immunity

Do You Have Prickly Heat Rash – Symptoms, Causes And Treatment

Healthy No-Cook Recipes You Can Try

How Do You Calorie Count – Numbers And Nutrients

Unexpected Signs Of Dehydration – Safety And Precaution Measures

As the U.S. gears up for the peak summer travel season, a new COVID-19 variant known as NB.1.8.1—or informally, "Nimbus" has rapidly taken center stage in the ongoing pandemic landscape. First identified through international traveler screening in March 2025, the highly contagious Omicron subvariant is now responsible for an estimated 37% of COVID-19 cases in the country, according to the CDC’s latest two-week analysis ending June 7.NB.1.8.1 is a descendant of the Omicron recombinant lineage XDV.1.5.1 and possesses several spike protein mutations that have the potential to make it more transmissible and immune-evading with respect to immunity developed from prior infections or vaccinations. Nicknamed "Nimbus" by Canadian evolutionary biologist T. Ryan Gregory, the moniker has picked up steam on social media and public health discourse.Although total test positivity is still relatively low in the U.S. at approximately 3%, the swift rise of Nimbus to become the second most prevalent variant—second only to LP.8.1 at 38%—has raised alarm among virologists and public health professionals. Although present infection and hospitalization levels are still within control, experts are warning of the possibility of a summer spike akin to cycles experienced in earlier years.What Are The Painful Tell-Tale Symptoms of New Covid Variant?One of the clearest indicators of the NB.1.8.1 strain is a symptom described by patients as a "razor blade feeling" in the throat. This sore throat—dull and stabbing particularly when swallowing—is reported more often among Nimbus sufferers than in previous strains. Specialists advise rest, hydration, and painkillers to treat this symptom.Other frequently reported symptoms are fatigue, nasal congestion, cough, fever, muscle pain, and mild breathing difficulties, in line with previous Omicron subvariants.On May 23, the World Health Organization designated NB.1.8.1 as a "variant under monitoring," noting its rapid worldwide spread and potentially high mutations. As of May 18, it was reported in more than 22 nations and now accounts for more than 10.7% of cases of COVID-19 worldwide.In the United States, sequences deposited at GISAID corroborate its presence in at least 14 states, with public health officials anticipating wider geographic spread over the next few weeks. Trends from foreign health agencies and increasing hospitalizations in the U.K. imply a worldwide trend of enhanced transmissibility despite incomplete sequencing data.How Dangerous Is Nimbus COVID Variant?Although Nimbus is certainly more infectious, to date, there is no indication that it produces more severe illness than the previous ones. The WHO and the CDC both confirm that authorized COVID-19 vaccines continue to work against this variant, although breakthrough infections may happen.The United Kingdom Health Security Agency (UKHSA) recently posted a near 10% increase in COVID hospitalizations and a 6.9% rise in cases in one week. UKHSA's deputy director, Dr. Gayatri Amirthalingam, stressed the point that while the variant is spreading, there is no immediate evidence of heightened severity of disease.Will Nimbus Lead to a U.S. Summer Surge?In the past, COVID-19 has increased twice a year in the United States—in the winter and then in the summer months, from June through August. That has been the case since 2020, and having a new, more contagious variant coupled with more travel and gatherings could set off another wave.Experts warn that while population immunity in the U.S. is very high—with more than 90% of Americans having been infected or vaccinated—immunity does fade over time. Couple this with the immune-evasive nature of NB.1.8.1, and the recipe for a possible surge in cases is there.Presently, WHO claims that current vaccines are protective against Nimbus. New COVID vaccines for the 2025–2026 season, designed to address LP.8.1, are set to be distributed this fall. In a contentious decision, Health and Human Services Secretary Robert F. Kennedy Jr. stated that the vaccines will only be available for high-risk populations: persons above 65 years and persons between the ages of 12–64 with at least one comorbidity.The CDC has also at the same time revised its guidelines, no longer advising routine COVID vaccination of healthy pregnant women and children—a step that most obstetricians and pediatricians object to.How Can You Stay Safe?With COVID wastewater levels still low and hospitalization rates stable, there is no need for mass panic. However, staying informed and cautious is key. Individuals experiencing symptoms like razor-sharp throat pain, fever, or congestion should consider testing, isolate if positive, and seek medical attention if symptoms worsen—especially if they belong to high-risk groups.Visitors are urged to watch for regional strain patterns, maintain proper hygiene, and wear masks in crowded or poorly ventilated spaces during peak travel seasons.NB.1.8.1, or the "Nimbus" strain, is another chapter in the continuing COVID-19 tale. Although it seems no worse than past strains, its speed and its sore, razor-like throat mark it as a reminder that the virus is still evolving.Public health officials emphasize that vaccines continue to provide robust protection and must be employed as a first line of defense, particularly among those who are most vulnerable. While summer progresses, the emergence of Nimbus necessitates close observation, public awareness, and redoubled focus on preventive health.

over 1 in 3 covid cases in us now are because of new ‘nimbus’ variant: experts flag this painful symptom

Ishita Roy

India Sees 11 Deaths In 24 Hours Despite A Drop In Active COVID Cases: Are Elderly With Comorbidities At Maximum Risk?

india sees 11 deaths in 24 hours despite a drop in active covid cases: are elderly with comorbidities at maximum risk?

14-Year-Old Boy Dies Days After Complaining Of 'Headache And Fever' From Rare Bacterial Infection

14-year-old boy dies days after complaining of 'headache and fever' from rare bacterial infection

This New Daily Pill Lowers ‘Bad Cholesterol’ And Heart Attack Risk By 30% In Just 12 Weeks

this new daily pill lowers ‘bad cholesterol’ and heart attack risk by 30% in just 12 weeks

A dangerous airborne fungus that has the potential to rot human tissue from the inside is spreading at a considerably increasing rate across the United States. It has prompted concerns among the medical professionals and public health authorities. <span>Aspergillus fumigatus</span>. This is said to be the culprit behind this surge and poses a risk to especially those whose immune system had been compromised. The cases are becoming harder to treat due to widespread drug resistance and climate-linked proliferation. 

The World Health Organization (WHO) has classified Aspergillus fumigatus as a “critical priority” due to its high mortality rate and growing resistance to existing treatments.

It is called a silent invader for a reason. Once you inhale, the fungus can cause aspergillosis. This is a serious lung infection. The spores are microscopic, which mean hat people can breathe them in unknowingly. For patients who are already vulnerable medically, for instance, those battling cancer, asthma, HIV or recovering from organ transplants, the infection can lead to chronic lung disease, systemic organ failure, or even death. If invasive, it can also spread to your brain, hear, and kidneys.

Despite its potentially fatal consequences, aspergillosis is not classified as a reportable disease in the United States. This means infections are not systematically tracked, leaving health officials with limited data and making it harder to trace or contain outbreaks.

Between 2000 to 2013, hospitalizations have increased in the case of invasive aspergillosis in the US. The rate is reported by a 3% increased, annually. In 2014, the infection led to 15,000 hospital stays, with a cost up to $1.2 billion. 

As the US News notes, postmortem examinations in intensive care units suggest that aspergillosis is among the top four infections most likely to be fatal.

While about 400,000 Americans may be living with chronic pulmonary aspergillosis — the long-term form of the disease — invasive cases, though less frequent, are significantly deadlier. Survival rates drop sharply: just 59% of organ transplant patients and only 25% of stem cell transplant patients live beyond a year after infection.

The fungus thrives in hot, damp, and humid environment. They can also endure up to 120 degree Fahrenheit. This is especially true in compost or agricultural waste. States like Florida, Texas, Georgia, Louisiana, and California — with their humid climates and farming activity — are seeing some of the highest exposure levels. Cities such as New York, Houston, and Los Angeles are also at risk due to overcrowding, aging buildings, and limited ventilation.

According to a University of Manchester study, if fossil fuel use continues at current levels, Aspergillus fumigatus could expand its range by over 75% by 2100 — putting millions more at risk across the southern US.

What is making it even more difficult to control is the increasing drug resistance. Azole drugs — commonly used to treat human fungal infections — are also applied to protect crops. This dual-use, experts say, may be fueling cross-environmental resistance, with drug-resistant spores jumping from soil to humans.

A study published in Applied and Environmental Microbiology found resistant fungal strains in agricultural soil across at least seven US states. Some strains are resistant to multiple standard antifungals, making treatment increasingly difficult.

WHO has also urged pharmaceutical companies to invest in new antifungals, including children in drug trials, and enhance diagnostic and treatment protocols globally.

As of now, doctors recommend to avoid contact with soil, mold, and gardening. It is important to wear protective masks when in dusty areas, and ensure good air filtration at home. 

Aspergillus fumigatus

health news

us health

us health news

fungus spreading in US

A dangerous airborne fungus that has the potential to rot human tissue from the inside is spreading at a considerably increasing rate across the United States. It has prompted concerns among the medical professionals and public health authorities. Aspergillus fumigatus. This is said to be the culprit behind this surge and poses a risk to especially those whose immune system had been compromised. The cases are becoming harder to treat due to widespread drug resistance and climate-linked proliferation. The World Health Organization (WHO) has classified Aspergillus fumigatus as a “critical priority” due to its high mortality rate and growing resistance to existing treatments.Silent InvaderIt is called a silent invader for a reason. Once you inhale, the fungus can cause aspergillosis. This is a serious lung infection. The spores are microscopic, which mean hat people can breathe them in unknowingly. For patients who are already vulnerable medically, for instance, those battling cancer, asthma, HIV or recovering from organ transplants, the infection can lead to chronic lung disease, systemic organ failure, or even death. If invasive, it can also spread to your brain, hear, and kidneys.Despite its potentially fatal consequences, aspergillosis is not classified as a reportable disease in the United States. This means infections are not systematically tracked, leaving health officials with limited data and making it harder to trace or contain outbreaks.Infections On The RiseBetween 2000 to 2013, hospitalizations have increased in the case of invasive aspergillosis in the US. The rate is reported by a 3% increased, annually. In 2014, the infection led to 15,000 hospital stays, with a cost up to $1.2 billion. As the US News notes, postmortem examinations in intensive care units suggest that aspergillosis is among the top four infections most likely to be fatal.While about 400,000 Americans may be living with chronic pulmonary aspergillosis — the long-term form of the disease — invasive cases, though less frequent, are significantly deadlier. Survival rates drop sharply: just 59% of organ transplant patients and only 25% of stem cell transplant patients live beyond a year after infection.What Is Causing Its Spread?The fungus thrives in hot, damp, and humid environment. They can also endure up to 120 degree Fahrenheit. This is especially true in compost or agricultural waste. States like Florida, Texas, Georgia, Louisiana, and California — with their humid climates and farming activity — are seeing some of the highest exposure levels. Cities such as New York, Houston, and Los Angeles are also at risk due to overcrowding, aging buildings, and limited ventilation.According to a University of Manchester study, if fossil fuel use continues at current levels, Aspergillus fumigatus could expand its range by over 75% by 2100 — putting millions more at risk across the southern US.What is making it even more difficult to control is the increasing drug resistance. Azole drugs — commonly used to treat human fungal infections — are also applied to protect crops. This dual-use, experts say, may be fueling cross-environmental resistance, with drug-resistant spores jumping from soil to humans.A study published in Applied and Environmental Microbiology found resistant fungal strains in agricultural soil across at least seven US states. Some strains are resistant to multiple standard antifungals, making treatment increasingly difficult.WHO has also urged pharmaceutical companies to invest in new antifungals, including children in drug trials, and enhance diagnostic and treatment protocols globally.Preventive MeasuresAs of now, doctors recommend to avoid contact with soil, mold, and gardening. It is important to wear protective masks when in dusty areas, and ensure good air filtration at home. 

lethal fungus is spreading across many us states, why is it concerning?

Health & Wellness

‘The Boys’ Star Erin Moriarty Reveals Graves’ Disease Diagnosis- Talks About Symptoms She Overlooked And Urges Fans 'Go Get Checked'

‘the boys’ star erin moriarty reveals graves’ disease diagnosis- talks about symptoms she overlooked and urges fans 'go get checked'

Why Your 20s and 30s Aren’t 'Too Early' To Worry About Diabetes Risks

why your 20s and 30s aren’t 'too early' to worry about diabetes risks

The unexpected and tragic death of Greenville, South Carolina 14-year-old William "Will" Hand stunned the local population and has caused worldwide concern about a rare but virulent bacterial infection: meningococcal septicemia or meningococcemia. Will, a graduating eighth-grader at Hughes Academy of Science and Technology, died in a matter of days of showing symptoms, which emphasizes the importance of early diagnosis, vaccination, and public awareness.

William Hand was not just an excellent student but also a well-loved friend, athlete, jokester, and music lover. Friends and family have referred to him as the "life of the party," defining his personality by humor, sportiness, and a talent for transforming everyday situations into memories that never faded. He had just finished eighth grade and was anticipating a summer of baseball, good times, and friends. Sadly, his life was ended on June 8th, just a few days after he developed what appeared to be flu-like symptoms.

Will's mother, Megan Hand, reported that her son passed away due to meningococcal septicemia—a rare and usually deadly bloodstream infection caused by the bacterium <span>Neisseria meningitidis</span>. Within hours of developing symptoms of illness, such as a high fever and rash, Will's situation rapidly worsened in spite of aggressive treatment from the staff at Prisma Health Children's Hospital.

Meningococcemia is when Neisseria meningitidis enters the blood and starts to proliferate indiscriminately. As Dr. Anna-Kathryn Burch, a pediatric infectious disease expert for Prisma Health, explained, "The infection occurs so rapidly, and when it begins going, sometimes it is really difficult to save the individual who is infected with the bacteria."

The illness is spread by respiratory secretions and saliva—most often through close contact or sharing utensils and drinks. Symptoms typically start suddenly and can include high fever, severe headache, light sensitivity, nausea, vomiting, and petechial rash. This red rash, which looks like broken capillaries beneath the skin, does not fade when pressed and is an important indicator of bloodstream infection.

Dr. Burch made it clear that though <span>meningococcal disease</span> is unusual, it is very aggressive and needs prompt medical care. "It's not your average viral rash. If you push your finger on it and the spots don't dissipate, it's a medical emergency."

The South Carolina Department of Health and Environmental Control (DHEC) has documented 12 cases of Neisseria meningitidis in the past 18 months—eight in the Upstate area, four deaths. Although the public has become concerned, DHEC insists that this is not an outbreak. "We track all cases and have determined there is no epidemiological connection among cases," a spokesperson explained.

Nonetheless, the public is understandably upset. Will's tale has resonated with many, increasing discussion regarding bacterial meningitis, its signs, and the necessity of prevention.

Meningococcemia is an uncommon but aggressively progressing infection by bacteria that invades the blood, usually causing severe and even fatal complications if left untreated. The following is a description of its signs of onset, underlying causes, and ensuing severe complications.

Meningococcemia comes on rapidly—typically within hours—and usually is described by patients as the worst they've ever experienced. Initial symptoms may resemble flu or an overall viral illness but worsen rapidly. Watch out for:

<ul><li>Cold hands and feet</li><li>Severe leg pain in the muscles</li><li>Extreme lethargy or fatigue</li><li>Rapid or shallow breathing</li><li>Severe abdominal pain</li><li>Shivering or chills, also called "rigors"</li><li>Skin color changes, such as paleness or skin patches that are discolored</li><li>Characteristic rash</li></ul>

Begins as tiny, flat red spots (petechiae) in areas where pressure tends to cause them, such as the armpits, waistband, ankles, elbows, or inner thighs. It can progress to larger purplish patches (purpura) as the illness becomes more severe.

The disease is due to Neisseria meningitidis bacteria (also referred to as meningococcus). It usually enters the body when inhaled and spreads either of two ways:

To the blood → giving rise to meningococcemia.

To the brain and spinal cord → resulting in meningitis.

During meningococcemia, the bacteria lyse blood vessels, disrupting oxygen supply to tissues—a characteristic of its life-threatening potential.

<h2>Importance and Role of Vaccation</h2>

The Centers for Disease Control and Prevention (CDC) suggests routine immunization of adolescents against meningococcal disease. Two FDA-licensed vaccines exist, the Meningococcal ACWY vaccine, generally given at age 11 with a booster shot in 16, and the Meningococcal B vaccine, which can be suggested depending on personal risk factors.

"These vaccines represent our best defense against this fatal infection," added Dr. Burch. "They don't protect against every strain, but they greatly lower the risk of severe illness and death." Parents can speak to their healthcare providers about vaccinating their children, particularly as they begin middle school and high school.

Will's obituary is a testament to a bright, bubbly teenager who brightened up every space. "His passing leaves an emptiness that can never be filled, but his joyous personality, winning smile, and charismatic presence will live in the hearts of all who knew him," the family wrote. "This infection is uncommon," Dr. Burch said, "but when it occurs, every second counts.

rare infection

meningococcal disease

rare bacterial infection

teen meningitis death

neisseria meningitidis

meningococcemia symptoms

cdc vaccine recommendations

prisma health south carolina

The unexpected and tragic death of Greenville, South Carolina 14-year-old William "Will" Hand stunned the local population and has caused worldwide concern about a rare but virulent bacterial infection: meningococcal septicemia or meningococcemia. Will, a graduating eighth-grader at Hughes Academy of Science and Technology, died in a matter of days of showing symptoms, which emphasizes the importance of early diagnosis, vaccination, and public awareness.William Hand was not just an excellent student but also a well-loved friend, athlete, jokester, and music lover. Friends and family have referred to him as the "life of the party," defining his personality by humor, sportiness, and a talent for transforming everyday situations into memories that never faded. He had just finished eighth grade and was anticipating a summer of baseball, good times, and friends. Sadly, his life was ended on June 8th, just a few days after he developed what appeared to be flu-like symptoms.Will's mother, Megan Hand, reported that her son passed away due to meningococcal septicemia—a rare and usually deadly bloodstream infection caused by the bacterium Neisseria meningitidis. Within hours of developing symptoms of illness, such as a high fever and rash, Will's situation rapidly worsened in spite of aggressive treatment from the staff at Prisma Health Children's Hospital.What is Meningococcemia?Meningococcemia is when Neisseria meningitidis enters the blood and starts to proliferate indiscriminately. As Dr. Anna-Kathryn Burch, a pediatric infectious disease expert for Prisma Health, explained, "The infection occurs so rapidly, and when it begins going, sometimes it is really difficult to save the individual who is infected with the bacteria."The illness is spread by respiratory secretions and saliva—most often through close contact or sharing utensils and drinks. Symptoms typically start suddenly and can include high fever, severe headache, light sensitivity, nausea, vomiting, and petechial rash. This red rash, which looks like broken capillaries beneath the skin, does not fade when pressed and is an important indicator of bloodstream infection.Dr. Burch made it clear that though meningococcal disease is unusual, it is very aggressive and needs prompt medical care. "It's not your average viral rash. If you push your finger on it and the spots don't dissipate, it's a medical emergency."The South Carolina Department of Health and Environmental Control (DHEC) has documented 12 cases of Neisseria meningitidis in the past 18 months—eight in the Upstate area, four deaths. Although the public has become concerned, DHEC insists that this is not an outbreak. "We track all cases and have determined there is no epidemiological connection among cases," a spokesperson explained.Nonetheless, the public is understandably upset. Will's tale has resonated with many, increasing discussion regarding bacterial meningitis, its signs, and the necessity of prevention.Symptoms of MeningococcemiaMeningococcemia is an uncommon but aggressively progressing infection by bacteria that invades the blood, usually causing severe and even fatal complications if left untreated. The following is a description of its signs of onset, underlying causes, and ensuing severe complications.Meningococcemia comes on rapidly—typically within hours—and usually is described by patients as the worst they've ever experienced. Initial symptoms may resemble flu or an overall viral illness but worsen rapidly. Watch out for:Cold hands and feetSevere leg pain in the musclesExtreme lethargy or fatigueRapid or shallow breathingSevere abdominal painShivering or chills, also called "rigors"Skin color changes, such as paleness or skin patches that are discoloredCharacteristic rashBegins as tiny, flat red spots (petechiae) in areas where pressure tends to cause them, such as the armpits, waistband, ankles, elbows, or inner thighs. It can progress to larger purplish patches (purpura) as the illness becomes more severe.What Causes Meningococcemia?The disease is due to Neisseria meningitidis bacteria (also referred to as meningococcus). It usually enters the body when inhaled and spreads either of two ways:To the blood → giving rise to meningococcemia.To the brain and spinal cord → resulting in meningitis.During meningococcemia, the bacteria lyse blood vessels, disrupting oxygen supply to tissues—a characteristic of its life-threatening potential.Importance and Role of VaccationThe Centers for Disease Control and Prevention (CDC) suggests routine immunization of adolescents against meningococcal disease. Two FDA-licensed vaccines exist, the Meningococcal ACWY vaccine, generally given at age 11 with a booster shot in 16, and the Meningococcal B vaccine, which can be suggested depending on personal risk factors."These vaccines represent our best defense against this fatal infection," added Dr. Burch. "They don't protect against every strain, but they greatly lower the risk of severe illness and death." Parents can speak to their healthcare providers about vaccinating their children, particularly as they begin middle school and high school.Will's obituary is a testament to a bright, bubbly teenager who brightened up every space. "His passing leaves an emptiness that can never be filled, but his joyous personality, winning smile, and charismatic presence will live in the hearts of all who knew him," the family wrote. "This infection is uncommon," Dr. Burch said, "but when it occurs, every second counts.

Worried About Heart Problems Before 60? Cardiologist Shares 10 Must-Know Rules

worried about heart problems before 60? cardiologist shares 10 must-know rules

Nutrition

rfk jr. claims seed oils are 'poison' but this what they actually do to your body

CDC Budget Cuts May Hit Women With Chronic Diseases Like Sickle Cell The Hardest

cdc budget cuts may hit women with chronic diseases like sickle cell the hardest

A new once-in-a-day medication, <span>Obicetrapib</span>, has the attention of the medical within the international medical community since recent Phase 3 clinical trial results showed it had the potential to lower LDL ("bad") cholesterol and lipoprotein(a), both primary risk factors for heart attack and stroke. What makes this breakthrough. so special is its easy, once-a-day oral tablet form—a potential game-changer for millions who struggle to keep their cholesterol under control despite already being on aggressive treatment plans.

The breaththrough BROADWAY trial, conducted by Monash University's Victorian Heart Institute in Australia under the leadership of Professor Stephen Nicholls, recruited more than 2,500 patients with an age of approximately 65. They were either suffering from pre-existing cardiovascular disease or genetically elevated cholesterol levels and were already on the highest tolerable intensity of conventional cholesterol medications.

Members of the trial group were given either the experimental drug Obicetrapib or a placebo, in addition to their standard cholesterol-lowering treatments. In as little as 12 weeks, individuals taking Obicetrapib had a 32.6% reduction in LDL cholesterol and a 33.5% reduction in lipoprotein(a) (Lp[a])—a remarkable achievement, particularly given that Lp(a) has been notoriously resistant to treatment by conventional medicine.

In spite of the availability of statins and other lipid-lowering drug therapies, much of the patient population still cannot achieve guideline-recommended targets for LDL cholesterol and are thus at ongoing risk of heart attack and stroke.

LDL cholesterol can build up in blood vessels, forming plaques that narrow arteries and reduce blood flow—events that can lead to a heart attack or stroke. Lp(a), on the other hand, is an inherited protein that promotes blood clotting and arterial damage, with few if any effective treatments on the market.

"Such individuals, it appears, may not achieve their cholesterol levels low enough despite the optimal available therapies," explained Professor Nicholls. "Obicetrapib represents a promising new alternative—not only did it reduce LDL cholesterol by more than 30%, but we also witnessed a decrease in Lp(a), which is much more difficult to lower and is associated with elevated heart disease risk."

In contrast to many therapies that act on one type of lipid, Obicetrapib has the advantage of reducing both LDL and Lp(a)—a feat few drugs have managed to do. Having this dual effect in a single once-a-day oral tablet is an added convenience for already-complex medication regimens for patients.

Another noteworthy feature of the trial was how tolerable the drug was. Obicetrapib was widely welcomed by most participants, having no apprehending side effects or safety issues, based on the findings reported in The New England Journal of Medicine and presented during the European Atherosclerosis Society Congress in Glasgow.

Although Obicetrapib's impact in lowering LDL and Lp(a) is quite remarkable, the research didn't account for direct measures such as real reduction in heart attacks or strokes. Still, the relationship between lower LDL/Lp(a) and decreased cardiovascular risk has long been documented in medical research.

What this trial does, however, is offer strong evidence for a next-generation lipid-lowering therapy that could address the needs of patients who haven’t responded well to existing treatments. In clinical settings, even a 1% drop in LDL can translate to significant reductions in cardiovascular events over time.

Obicetrapib is being developed by NewAmsterdam Pharma, a Netherlands-based company. Although the BROADWAY trial has shown encouraging early findings, further studies on long-term endpoints—such as actual decreases in heart attacks, strokes, and cardiovascular mortality—are needed before regulatory bodies such as the FDA can grant approval for its broad use.

There's also the issue of how well Obicetrapib would work in individuals specifically chosen for high Lp(a), something this trial wasn't set up to test. Future research will explore these subpopulations more deeply.

Even so, authorities think the early indication is promising. "A valuable weapon in the war against heart disease," replied Nicholls. "It's easy to use, it works, and it could help bridge the gap for those who've exhausted their choices."

As cardiovascular disease continues to be the global leading cause of death, advances such as Obicetrapib could be the solution to confronting what is still a chronic global health problem. A once-a-day tablet that lowers both LDL and Lp(a) in a safe manner could transform primary and secondary prevention in cardiology, especially among high-risk patients already on multiple drugs.

Convenience and adherence are critical to the success of treatment, particularly in populations that are elderly or have multiple chronic diseases. A once-daily formulation ensures fewer side effects and increases the chances that patients will adhere to regimen compliance, leading to improved long-term outcomes.

As more research is conducted before Obicetrapib is an everyday addition to managing cholesterol, this experimental medication holds real potential. By successfully lowering two of the top heart disease villains in a single easy dose, it can potentially close a very important treatment gap for those most at risk.

heart health

obicetrapib

cholesterol pill 2025

heart attack prevention

ldl cholesterol reduction

lipoprotein(a) treatment

cardiovascular drug breakthrough

once-daily heart pill

A new once-in-a-day medication, Obicetrapib, has the attention of the medical within the international medical community since recent Phase 3 clinical trial results showed it had the potential to lower LDL ("bad") cholesterol and lipoprotein(a), both primary risk factors for heart attack and stroke. What makes this breakthrough. so special is its easy, once-a-day oral tablet form—a potential game-changer for millions who struggle to keep their cholesterol under control despite already being on aggressive treatment plans.The breaththrough BROADWAY trial, conducted by Monash University's Victorian Heart Institute in Australia under the leadership of Professor Stephen Nicholls, recruited more than 2,500 patients with an age of approximately 65. They were either suffering from pre-existing cardiovascular disease or genetically elevated cholesterol levels and were already on the highest tolerable intensity of conventional cholesterol medications.Members of the trial group were given either the experimental drug Obicetrapib or a placebo, in addition to their standard cholesterol-lowering treatments. In as little as 12 weeks, individuals taking Obicetrapib had a 32.6% reduction in LDL cholesterol and a 33.5% reduction in lipoprotein(a) (Lp[a])—a remarkable achievement, particularly given that Lp(a) has been notoriously resistant to treatment by conventional medicine.In spite of the availability of statins and other lipid-lowering drug therapies, much of the patient population still cannot achieve guideline-recommended targets for LDL cholesterol and are thus at ongoing risk of heart attack and stroke.LDL cholesterol can build up in blood vessels, forming plaques that narrow arteries and reduce blood flow—events that can lead to a heart attack or stroke. Lp(a), on the other hand, is an inherited protein that promotes blood clotting and arterial damage, with few if any effective treatments on the market."Such individuals, it appears, may not achieve their cholesterol levels low enough despite the optimal available therapies," explained Professor Nicholls. "Obicetrapib represents a promising new alternative—not only did it reduce LDL cholesterol by more than 30%, but we also witnessed a decrease in Lp(a), which is much more difficult to lower and is associated with elevated heart disease risk."In contrast to many therapies that act on one type of lipid, Obicetrapib has the advantage of reducing both LDL and Lp(a)—a feat few drugs have managed to do. Having this dual effect in a single once-a-day oral tablet is an added convenience for already-complex medication regimens for patients.Another noteworthy feature of the trial was how tolerable the drug was. Obicetrapib was widely welcomed by most participants, having no apprehending side effects or safety issues, based on the findings reported in The New England Journal of Medicine and presented during the European Atherosclerosis Society Congress in Glasgow.Although Obicetrapib's impact in lowering LDL and Lp(a) is quite remarkable, the research didn't account for direct measures such as real reduction in heart attacks or strokes. Still, the relationship between lower LDL/Lp(a) and decreased cardiovascular risk has long been documented in medical research.What this trial does, however, is offer strong evidence for a next-generation lipid-lowering therapy that could address the needs of patients who haven’t responded well to existing treatments. In clinical settings, even a 1% drop in LDL can translate to significant reductions in cardiovascular events over time.Obicetrapib is being developed by NewAmsterdam Pharma, a Netherlands-based company. Although the BROADWAY trial has shown encouraging early findings, further studies on long-term endpoints—such as actual decreases in heart attacks, strokes, and cardiovascular mortality—are needed before regulatory bodies such as the FDA can grant approval for its broad use.There's also the issue of how well Obicetrapib would work in individuals specifically chosen for high Lp(a), something this trial wasn't set up to test. Future research will explore these subpopulations more deeply.Even so, authorities think the early indication is promising. "A valuable weapon in the war against heart disease," replied Nicholls. "It's easy to use, it works, and it could help bridge the gap for those who've exhausted their choices."As cardiovascular disease continues to be the global leading cause of death, advances such as Obicetrapib could be the solution to confronting what is still a chronic global health problem. A once-a-day tablet that lowers both LDL and Lp(a) in a safe manner could transform primary and secondary prevention in cardiology, especially among high-risk patients already on multiple drugs.Convenience and adherence are critical to the success of treatment, particularly in populations that are elderly or have multiple chronic diseases. A once-daily formulation ensures fewer side effects and increases the chances that patients will adhere to regimen compliance, leading to improved long-term outcomes.As more research is conducted before Obicetrapib is an everyday addition to managing cholesterol, this experimental medication holds real potential. By successfully lowering two of the top heart disease villains in a single easy dose, it can potentially close a very important treatment gap for those most at risk.

About Us

Contact Us

Terms & Conditions

Privacy Policy

Company

Health and Me is a premium website with content written and curated to function as a handbook for all Health concerns.

Over 1 In 3 COVID Cases In US Now Are Because Of New ‘Nimbus’ Variant: Experts Flag This Painful Symptom

Quick Stories

Lethal Fungus Is Spreading Across Many US States, Why Is It Concerning?

14-Year-Old Boy Dies Days After Complaining Of 'Headache And Fever' From Rare Bacterial Infection

This New Daily Pill Lowers ‘Bad Cholesterol’ And Heart Attack Risk By 30% In Just 12 Weeks

Health Conditions A-Z

Lethal Fungus Is Spreading Across Many US States, Why Is It Concerning?

90% Of Young Men In Their 20s And 30s Are Unaware Of This Fast-Rising Cancer Threat

RFK Jr. Claims Seed Oils Are 'Poison' But This What They Actually Do To Your Body